While SHP099 alone showed anti‐tumour effect in GIST mouse model, the evidence from both preclinical and clinical studies strongly supports the combination of SHP2 inhibitors with RTK inhibitors for advanced cancers.17 This evidence concerns the gene PTPN11 and cancer.